A real-world retrospective cohort study: the clinical outcomes and characteristics of platinum-resistant recurrent ovarian cancer
In this real-world cohort, we found that patients diagnosed with PRROC, particularly those with a PFI of >3-6 months, experienced substantial benefits from the re-administration of platinum agents. Thus, platinum rechallenge therapy could represent a promising treatment approach for PRROC. Biomarkers of platinum sensitivity are needed in clinical practice to identify potential responders who should be offered re-treatment with platinum.
Authors
- Bei Zhang (ORCID: https://orcid.org/0000-0003-1966-7676)
- Rosa A. Salcedo‐Hernández (ORCID: https://orcid.org/0000-0003-4537-8034)
- Colton Ladbury (ORCID: https://orcid.org/0000-0002-2668-3415)
- Jörg Wischhusen (ORCID: https://orcid.org/0000-0002-0390-4297)
- Lei Kuang
- Guiping Wan (ORCID: https://orcid.org/0000-0001-6940-938X)
- Qing Wang (ORCID: https://orcid.org/0000-0002-5075-2951)
- Qi Chen (ORCID: https://orcid.org/0000-0002-0658-7629)
- Jingbo Zhang (ORCID: https://orcid.org/0000-0002-5683-9660)
- Yanyu Li (ORCID: https://orcid.org/0000-0002-1416-9216)
- Jiayun Zhou (ORCID: https://orcid.org/0000-0002-4283-9627)
- Xinhui Yang
- Boyang Liu
- Zeyuan Yin
Institutions
- City Of Hope National Medical Center (US)
- Nanjing University of Chinese Medicine (CN)
- Xuzhou Medical College (CN)
- University of Würzburg (DE)
- University of Manchester (GB)
- National Cancer Center (US)
- Xuzhou Central Hospital (CN)
- Instituto Nacional de Cancerología (MX)
Publication Details
- Journal
- Translational Cancer Research
- Published
- 2025-05-01
- DOI
- https://doi.org/10.21037/tcr-2025-641
- Citations
- 1
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.70